Research progresses in the pathogenesis of anaplastic large cell lymphoma

Chinese Journal of Cancer

Volumn 30, Issue 6, 2011, Pages 392-399

  Shi, Xiao Lan ^a   Tang, Xiao Wen ^a   Wu, De Pei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Anaplastic large cell lymphoma; Anaplastic lymphoma kinase; Pathogenesis

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT;

ALK GENE; CELL INVASION; CELL MIGRATION; CELL TRANSFORMATION; CLINICAL FEATURE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE STRUCTURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANTIGENS, CD30; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; RADIOTHERAPY; RECEPTOR PROTEIN-TYROSINE KINASES; STEM CELL TRANSPLANTATION;

EID: 79959315097     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.30.0392     Document Type: Review

References (49)

1. + anaplastic large-cell lymphoma [J]. Blood, 2007,110(7):2259-2267.
2. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma [J]. Science, 1994,263(5151):1281-1284.
3. Pulford K, Mason DY. CD246 Antigen. Leucocyte Typing VII. In: Mason DY, et al. editors. White cell differentiation antigens [M]. Oxford: Oxford University Press, 2002:694-696.
4. Li R, Morris SW. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy [J]. Med Res Rev, 2008,28(3):372-412.
5. Pulford K, Morris SW, Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer [J]. J Cell Physiol, 2004, 199(3):330-358.
6. Falini B, Pulford K, Pucciarini A, et al. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK [J]. Blood, 1999,94 (10):3509-3515.
7. Fujimoto J, Shiota M, Iwahara T, et al. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a KM lymphoma cell line with chromosomal translocation t(2;5) [J]. Proc Natl Acad Sci USA, 1996,93(9):4181-4186.
8. Cussac D, Greenland C, Roche S, et al. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity [J]. Blood, 2004,103(4):1464-1471.
9. Feng GS. Shp-2 tyrosine phosphatase: signaling one cell or many [J]. Exp Cell Res, 1999,253(1):47-54.
10. Voena C, Conte C, Ambrogio C, et al. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration [J]. Cancer Res, 2007,67(9):4278-4286.
11. Bai RY, Dieter P, Peschel C, et al. Nucelophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C- to mediate its mitogenicity [J]. Mol Cell Biol, 1998,18(12): 6951-6961.
12. Wellmann A, Doseeva V, Butscher W, et al. The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts [J]. FASEB J, 1997,11(12):965-972.
13. Leventaki V, Drakos E, Medeiros LJ, et al. NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma [J]. Blood, 2007,110(5):1621-1630.
14. Marzec M, Kasprzycka M, Liu X, et al. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway [J]. Oncogene, 2007,26(38):5606-5614.
15. Zamo A, Chiarle R, Piva R, et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death [J]. Oncogene, 2002,21(7):1038-1047.
16. Amin HM, Medeiros LJ, Ma Y, et al. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma [J]. Oncogene, 2003,22(35): 5399-5407.
17. Lai R, Rassidakis GZ, Lin Q, et al. Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma [J]. Hum Pathol, 2005,36(9):939-944.
18. Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer [J]. Nat Rev Cancer, 2008,8(1):11-23.
19. Ruchatz H, Couccia AM, Stano P, et al. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells [J]. Exp Hematol, 2003,31 (4): 309-315.
20. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-in trinsic death machinery [J]. Cell, 1997,91(2):231-241.
21. Bai RY, Ouyang T, Miething C, et al. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic pathway [J]. Blood, 2000,96(13):4319-4127.
22. Rassidakis GZ, Feretzaki M, Atwell C, et al. Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma [J]. Blood, 2005,105 (2):827-829.
23. Gu TL, Tothova Z, Scheijen B, et al. NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a [J]. Blood, 2004,103(12):4622-4629.
24. Vega F, Medeiros LJ, Leventaki V, et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma [J]. Cancer Res, 2006,66(13): 6589-6597.
25. Hsu FY, Johnston PB, Burke KA, et al. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner [J]. Cancer Res, 2006,66 (18):9002-9008.
26. Ambrogio C, Voena C, Manazza AD, et al. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase [J]. Blood, 2005,106(12):3907-3916.
27. Colomba A, Courilleau D, Ramel D, et al. Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas [J]. Oncogene, 2007,27(19):2728-2736.
28. Han Y, Amin HM, Frantz C, et al. Restoration of shp1 expression by 5-aza-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma [J]. Leukemia, 2006,20 (9): 1602-1609.
29. Zhang Q, Wang HY, Liu X, et al. STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression [J]. Nature Med, 2007,13(11):1341-1348.
30. Wright CW, Rumble JM, Duckett CS. CD30 activates both the canonical and alternative NF-kB pathways in anaplastic large cell lymphoma cells [J]. J Biol Chem, 2007,282(14):10252-10262.
31. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues [M]. Lyon, France: IARC Press, 2008:312-316.
32. ten Berge RL, Oudejans JJ, Dukers DF, et al. Percentage of activated cytotoxic T lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker [J]. Leukemia, 2001,15(3):458-464.
33. Atkinson EA, Barry M, Darmon AJ, et al. Cytotoxic Tlymphocyte assisted suicide. Caspase 3 activation is primarily the result of the direct action of granzyme B [J]. J Biol Chem, 1998,273(33):21261-21266.
34. Alimonti JB, Shi L, Baijal PK, et al. Granzyme B induces BID-mediated cytochrome c release and mitochondrial permeability transition [J]. J Biol Chem, 2001,276(10):6974-6982.
35. Bladergroen BA, Meijer CJLM, ten Berge RL, et al. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? [J]. Blood, 2002,99(1):232-237.
36. Bird CH, Sutton VR, Sun J, et al. Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway [J]. Mol Cell Biol, 1998,18(11):6387-6398.
37. ten Berge RL, Meijer CJLM, Dukers DF, et al. Expression levels of apoptosis related proteins predict clinical outcome in anaplastic large cell lymphoma [J]. Blood, 2002,99(12):4540-4546.
38. Ioachim HL, Medeiros LJ. Ioachim's Lymph Node Pathology [M]. Fourth edition. Jonathan Pine, et al. editors. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Press, 2009:504-517.
39. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology [J]. Blood, 1998,91(6):2076-2084.
40. Falini B, Bigerna B, Fizzotti M, et al. ALK expression defines a distinct group of T/null lymphomas (ALK lymphomas) with a wide morphological spectrum [J]. Am J Pathol, 1998,153(3): 875-886.
41. + lymphoma: clinico-pathological findings and outcome [J]. Blood, 1999,93 (8): 2697-2706.
42. Wang FH, Li YH, Zeng J, et al. Clinical analysis of primary systemic anaplastic large cell lymphoma: a report of 57 cases [J]. Chin J Cancer, 2009,28(1):49-53.
43. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, et al. ALK- negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects-a review [J]. J Pathol, 2003,200(1):4-15.
44. + ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T- Cell Lymphoma Project [J]. Blood, 2008,111(12):5496-5504.
45. Lu Y, Zhao X, Wang E, et al. ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as leukemic phase [J]. Leuk Res, 2010,34(4):475-482.
46. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study [J]. Blood, 2004,103 (7):2474-2479.
47. Deconinck E, Lamy T, Foussard C, et al. Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial [J]. Br J Haematol, 2000,109(4):736-742.
48. Bordon V, De Paepe P, Dhooge C, et al. Successful treatment with allogeneic bone marrow transplantation of an early relapse of ALK-positive anaplastic large cell lymphoma [J]. Haematologica, 2005,90(3):ECR19.
49. Liso A, Tiacci E, Binazzi R, Pulford K, et al. Haploidentical peripheral-blood stemcell transplantation for ALK-positive anaplastic large-cell lymphoma [J]. Lancet Oncol, 2004,5(2): 127-128.